A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

被引：38
|
作者：
Chari, Ajai
Berdeja, Jesus G.
Oriol, Albert
van de Donk, Niels W. C. J.
Rodriguez, Paula
Askari, Elham
Mateos, Maria-Victoria
Minnema, Monique C.
Verona, Raluca
Girgis, Suzette
Prior, Thomas
Hilder, Brandi W.
Russell, Jeffery
Goldberg, Jenna D.
Krishnan, Amrita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133873
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Rasche, Leo
    Schinke, Carolina
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Singh, Indrajeet
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Hilder, Brandi W.
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
  • [32] The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma
    Schinke, Carolina
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (03)
  • [33] Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma
    Huang, Wentao
    Luo, Jie
    Li, Yifan
    Fei, Da
    Qin, Xia
    Li, Runsheng
    CANCER RESEARCH, 2022, 82 (12)
  • [34] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study
    Ito, Shigeki
    Kuroda, Yoshiaki
    Sunami, Kazutaka
    Matsue, Kosei
    Imada, Kazunori
    Tamura, Hideto
    Takamoto, Mikihiro
    Yamazaki, Hiroshi
    Fujikawa, Ei
    Pei, Lixia
    Masterson, Tara J.
    Campagna, Michela
    Lau, Bonnie W.
    Takamatsu, Yasushi
    BLOOD, 2024, 144 : 7011 - 7012
  • [35] Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D x CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
    Willemin, Marie-Emilie
    Gong, Jue
    Hilder, Brandi W.
    Masterson, Tara
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    De Zwart, Loeckie
    Girgis, Suzette
    Ma, Xuewen
    Ouellet, Daniele
    TARGETED ONCOLOGY, 2024, 19 (06) : 965 - 979
  • [36] Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1
    Catamero, Donna
    Purcell, Kiah
    Ray, Chloe
    Giacoia, Leora
    Leahey, Sheryl
    Born, Patricia
    Kruyswijk, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S314 - S315
  • [37] A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    D'Souza, Anita
    Shah, Nina
    Rodriguez, Cesar
    Voorhees, Peter M.
    Bueno, Orlando F.
    Ben Buelow
    Freise, Kevin J.
    Yue, Susan
    Pothacamury, Rajvineeth Kumar
    Polepally, Akshanth R.
    Vij, Ravi
    BLOOD, 2021, 138
  • [38] A Phase 1 First-in-Human Study of Abbv-383, a BCMA x CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
    Voorhees, Peter M.
    D'Souza, Anita
    Weisel, Katja
    Hurd, David Duane
    Teipel, Raphael
    Chung, Alfred
    Rodriguez, Cesar
    Tuchman, Sascha A.
    Korde, Neha
    Safah, Hana
    Bueno, Orlando F.
    Pumford, Neil
    Rosenberg, Tanya S.
    Pothacamury, Rajvineeth Kumar
    Ross, Jeremy A.
    Polepally, Akshanth R.
    Lee, Shane
    Jin, Ziyi
    Talati, Chetasi
    Vij, Ravi
    Kumar, Shaji K.
    BLOOD, 2022, 140 : 4401 - 4404
  • [39] Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
    Bal, Susan
    Kocoglu, M. Hakan
    Nadeem, Omar
    Htut, Myo
    Gregory, Tara
    Anderson, Larry D., Jr.
    Costa, Luciano J.
    Buchholz, Tonia J.
    Ziyad, Safiyyah
    Li, Meng
    Chen, Yanping
    Kaeding, Allison J.
    Burgess, Michael R.
    Hege, Kristen
    Berdeja, Jesus
    BLOOD, 2022, 140
  • [40] LEVELS AND PATTERNS OF ORPHAN-G-PROTEIN-COUPLED RECEPTOR, CLASS-C GROUP-5 MEMBER-D (GPRC5D) EXPRESSION IN NORMAL AND ABNORMAL PLASMA CELLS IN INDIAN MULTIPLE MYELOMA PATIENTS
    Jain, Disha
    Ghogale, Sitaram
    Deshpande, Nilesh
    Patil, Jagruti
    Girase, Karishma
    Chatterjee, Gaurav
    Rajpal, Sweta
    Patkar, Nikhil V.
    Bagal, Bhausaheb
    Jain, Hasmukh
    Sengar, Manju
    Hasan, Syed Khizer
    Khattry, Navin
    Subramanian, Papgudi G.
    Gujral, Sumeet
    Tembhare, Prashant R.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2024, 46 : 48 - 48
12345